Neurotrack Receives $2,000,000 Series A Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    120 Hawthorne Ave. Palo Alto, CA 94301
  • Company Description
    Neurotrack’s technology can diagnose the onset of Alzheimer’s Disease three to four years before symptoms occur. Based on ground-breaking research, it enables pharmaceutical companies and researchers to recruit qualified candidates for clinical trials, and more effectively measure drug efficacy, speeding up drug discovery and development.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The funds will be used to further develop and commercialize the company’s breakthrough technology, a visual cognitive test sensitive to damage in brain regions first impacted by Alzheimer’s disease.
  • M&A Terms
  • Venture Investor
    Founders Fund
  • Venture Investor
    The Social+Capital Partnership
  • Venture Investor

Trending on Xconomy